Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shixia Huang

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Nature Cell Biology|May 17, 2016
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiationThomas Welte, Ik Sun Kim, Lin Tian, et al.
Developmental Cell|April 20, 2021
The bone microenvironment increases phenotypic plasticity of ER<sup>+</sup> breast cancer cellsIgor L Bado, Weijie Zhang, Jingyuan Hu, et al.
Molecular Cancer Research : MCR|August 18, 2019
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast CancerVidyalakshmi Sethunath, Huizhong Hu, Carmine De Angelis, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
<i>SOD1</i> is a synthetic lethal target in <i>PPM1D</i>-mutant leukemia cellsLinda Zhang, Joanne I Hsu, Etienne D Braekeleer, et al.
NPJ Breast Cancer|May 1, 2020
BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progressionHanan S Elsarraj, Yan Hong, Darlene Limback, et al.
Elife|June 19, 2024
<i>SOD1</i> is a synthetic-lethal target in <i>PPM1D</i>-mutant leukemia cellsLinda Zhang, Joanne I Hsu, Etienne D Braekeleer, et al.
Nature Communications|February 14, 2024
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancerChandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancerXiaoyong Fu, Rinath Jeselsohn, Resel Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2024
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast CancerCristina Guarducci, Agostina Nardone, Douglas Russo, et al.
Nature Communications|February 2, 2020
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapyMeenu Sharma, Hiep Khong, Faisal Fa'ak, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Nature Cell Biology|May 17, 2016
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiationThomas Welte, Ik Sun Kim, Lin Tian, et al.
Developmental Cell|April 20, 2021
The bone microenvironment increases phenotypic plasticity of ER<sup>+</sup> breast cancer cellsIgor L Bado, Weijie Zhang, Jingyuan Hu, et al.
Molecular Cancer Research : MCR|August 18, 2019
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast CancerVidyalakshmi Sethunath, Huizhong Hu, Carmine De Angelis, et al.
Biorxiv : the Preprint Server for Biology|September 11, 2023
<i>SOD1</i> is a synthetic lethal target in <i>PPM1D</i>-mutant leukemia cellsLinda Zhang, Joanne I Hsu, Etienne D Braekeleer, et al.
NPJ Breast Cancer|May 1, 2020
BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progressionHanan S Elsarraj, Yan Hong, Darlene Limback, et al.
Elife|June 19, 2024
<i>SOD1</i> is a synthetic-lethal target in <i>PPM1D</i>-mutant leukemia cellsLinda Zhang, Joanne I Hsu, Etienne D Braekeleer, et al.
Nature Communications|February 14, 2024
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancerChandra Sekhar Amara, Karthik Reddy Kami Reddy, Yang Yuntao, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancerXiaoyong Fu, Rinath Jeselsohn, Resel Pereira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2024
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast CancerCristina Guarducci, Agostina Nardone, Douglas Russo, et al.
Nature Communications|February 2, 2020
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapyMeenu Sharma, Hiep Khong, Faisal Fa'ak, et al.
Pageof 10